Mosaic ImmunoEngineering Inc. (CPMV)
USD 1.0
(66.36%)
USD 1.0
(66.36%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2022 | 1.22 Million USD | 67.09% |
| 2021 | 735.14 Thousand USD | 0.0% |
| 2020 | - USD | 0.0% |
| 2019 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | -100.0% |
| 2009 | 3.12 Million USD | 2.65% |
| 2008 | 3.04 Million USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | -100.0% |
| 2004 | 570.09 Thousand USD | 17.95% |
| 2003 | 483.34 Thousand USD | -60.83% |
| 2002 | 1.23 Million USD | 57.64% |
| 2001 | 782.8 Thousand USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | -100.0% |
| 1998 | 356.62 Thousand USD | -30.15% |
| 1997 | 510.53 Thousand USD | 8062.01% |
| 1996 | 6255.00 USD | 0.0% |
| 1995 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q3 | 1.29 Million USD | 1.68% |
| 2023 Q1 | 1.25 Million USD | 2.17% |
| 2023 Q2 | 1.27 Million USD | 1.69% |
| 2022 Q3 | 1.19 Million USD | 3.13% |
| 2022 Q4 | 1.22 Million USD | 3.03% |
| 2022 FY | 1.22 Million USD | 67.09% |
| 2022 Q1 | 1.11 Million USD | 51.23% |
| 2022 Q2 | 1.15 Million USD | 3.99% |
| 2021 Q3 | 709.83 Thousand USD | 13.95% |
| 2021 Q4 | 735.14 Thousand USD | 3.57% |
| 2021 FY | 735.14 Thousand USD | 0.0% |
| 2021 Q1 | - USD | 0.0% |
| 2021 Q2 | 622.93 Thousand USD | 0.0% |
| 2020 Q2 | - USD | 0.0% |
| 2020 Q4 | - USD | 0.0% |
| 2020 FY | - USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2020 Q3 | - USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 Q4 | - USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2010 FY | - USD | -100.0% |
| 2010 Q2 | 3.12 Million USD | 0.66% |
| 2010 Q3 | 2.63 Million USD | -15.48% |
| 2010 Q1 | 3.1 Million USD | 0.64% |
| 2010 Q4 | - USD | -100.0% |
| 2009 Q2 | 3.04 Million USD | -1.1% |
| 2009 Q3 | 3.06 Million USD | 0.68% |
| 2009 Q4 | 3.08 Million USD | 0.64% |
| 2009 Q1 | 3.07 Million USD | -6.54% |
| 2009 FY | 3.12 Million USD | 2.65% |
| 2008 Q2 | - USD | 0.0% |
| 2008 FY | 3.04 Million USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q4 | 3.29 Million USD | 603.06% |
| 2008 Q3 | 468.06 Thousand USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2006 Q1 | - USD | -100.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2005 FY | - USD | -100.0% |
| 2005 Q4 | 716.09 Thousand USD | 15.19% |
| 2005 Q3 | 621.64 Thousand USD | 9.04% |
| 2005 Q2 | 570.09 Thousand USD | 50.48% |
| 2005 Q1 | 378.85 Thousand USD | -39.79% |
| 2004 FY | 570.09 Thousand USD | 17.95% |
| 2004 Q4 | 629.2 Thousand USD | 7.74% |
| 2004 Q1 | 1.11 Million USD | -4.13% |
| 2004 Q2 | 483.34 Thousand USD | -56.62% |
| 2004 Q3 | 584 Thousand USD | 20.82% |
| 2003 Q4 | 1.16 Million USD | -6.76% |
| 2003 Q3 | 1.24 Million USD | 1.02% |
| 2003 Q2 | 1.23 Million USD | -1.44% |
| 2003 Q1 | 1.25 Million USD | 17.06% |
| 2003 FY | 483.34 Thousand USD | -60.83% |
| 2002 FY | 1.23 Million USD | 57.64% |
| 2002 Q3 | 622.41 Thousand USD | -20.49% |
| 2002 Q1 | 749.4 Thousand USD | 330.64% |
| 2002 Q2 | 782.8 Thousand USD | 4.46% |
| 2002 Q4 | 1.06 Million USD | 71.85% |
| 2001 Q4 | 174.02 Thousand USD | 0.0% |
| 2001 FY | 782.8 Thousand USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 2000 Q1 | - USD | -100.0% |
| 1999 Q3 | 403.42 Thousand USD | 0.0% |
| 1999 FY | - USD | -100.0% |
| 1999 Q4 | 698.74 Thousand USD | 73.2% |
| 1998 FY | 356.62 Thousand USD | -30.15% |
| 1997 FY | 510.53 Thousand USD | 8062.01% |
| 1996 FY | 6255.00 USD | 0.0% |
| 1995 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 97.019% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 70.2% |
| SQZ Biotechnologies Company | 27.47 Million USD | 95.529% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 97.168% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 95.873% |
| Mesoblast Limited | 118.7 Million USD | 98.965% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -29.537% |
| Genus plc | 233.1 Million USD | 99.473% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 58.082% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 8.576% |
| Marizyme, Inc. | 18.71 Million USD | 93.437% |
| ContraFect Corporation | 2.88 Million USD | 57.363% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -63.781% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -806.626% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | 15.07% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 47.189% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 78.291% |
| MultiCell Technologies, Inc. | 202.58 USD | -606258.476% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 97.863% |
| EV Biologics, Inc. | 1.49 Million USD | 17.822% |
| Q BioMed Inc. | 4.1 Million USD | 70.113% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 96.289% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -94.954% |
| Biomind Labs Inc. | 735.54 Thousand USD | -67.001% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 99.284% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 90.549% |
| Skye Bioscience, Inc. | 4.61 Million USD | 73.385% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -38.319% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -767.989% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 79.078% |
| IMV Inc. | 28.88 Million USD | 95.747% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -4676.084% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 45.609% |
| GB Sciences, Inc. | 1.75 Million USD | 30.179% |
| Alpha Cognition Inc. | 1.22 Million USD | -0.655% |
| HST Global, Inc. | 98.31 Thousand USD | -1149.363% |
| CSL Limited | 12.18 Billion USD | 99.99% |
| Halberd Corporation | 150 Thousand USD | -718.907% |
| Enzolytics Inc. | 996.33 Thousand USD | -23.288% |
| Resverlogix Corp. | 6.49 Million USD | 81.076% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -157.248% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -380.594% |
| argenx SE | 20 Million USD | 93.858% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 97.304% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 54.651% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -11913.311% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.706% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -512.295% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 48.77% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -435.721% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 98.184% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 59.409% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -241.486% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 93.957% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -726.322% |
| BioStem Technologies, Inc. | 4.71 Million USD | 73.928% |
| ONE Bio Corp. | 19.71 Million USD | 93.769% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -390.987% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -393.873% |
| Agentix Corp. | 50 Thousand USD | -2356.722% |
| LadRx Corporation | 33.6 Thousand USD | -3555.184% |
| Cell Source, Inc. | 9.25 Million USD | 86.726% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -62.438% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -62.438% |
| NovAccess Global Inc. | 2.19 Million USD | 44.162% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 82.633% |
| Itoco Inc. | 228.37 Thousand USD | -437.865% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -482.231% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 75.349% |
| Kadimastem Ltd | 891.22 Thousand USD | -37.828% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -205.677% |
| CytoDyn Inc. | 30.07 Million USD | 95.916% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -153.645% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -249.118% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 84.292% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -902.744% |
| Rebus Holdings, Inc. | 310 Thousand USD | -296.245% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 74.059% |
| International Stem Cell Corporation | 4.17 Million USD | 70.599% |
| Bioxytran, Inc. | 1.92 Million USD | 36.189% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -1868.117% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 43.676% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 85.229% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 85.692% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | 21.03% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -358.344% |
| Neutra Corp. | 54.15 Thousand USD | -2168.19% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 32.876% |
| PureTech Health plc | 25.51 Million USD | 95.185% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -0.338% |
| IXICO plc | 472.02 Thousand USD | -160.233% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 92.076% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 98.027% |
| CSL Limited | 12.18 Billion USD | 99.99% |
| Cellectis S.A. | 92.77 Million USD | 98.676% |